Erythropoietin stimulates fibroblast growth factor 23 (FGF23) in mice and men

• Published in: Pflügers Archiv Vol. 470; no. 10; pp. 1569 - 1582
• Main Authors: Daryadel, Arezoo, Bettoni, Carla, Haider, Thomas, Imenez Silva, Pedro H., Schnitzbauer, Udo, Pastor-Arroyo, Eva Maria, Wenger, Roland H., Gassmann, Max, Wagner, Carsten A.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01-10-2018; Springer Nature B.V
• Subjects: Biomedical and Life Sciences; Biomedicine; Bone marrow; Cell Biology; Dietary intake; Erythropoiesis; Erythropoietin; Fibroblast growth factor 23; Fibroblasts; Gene expression; Growth factors; Human Physiology; Hypoxia; Iron deficiency; Kidneys; Metabolism; Molecular Medicine; Neurosciences; Nutrient deficiency; Osteocytes; Osteoprogenitor cells; Parathyroid; Parathyroid hormone; Receptors; Rodents; Signaling and Cell Physiology; Transgenic mice; Vitamin D3; Vitamin D3; Bone; Erythropoietin; FGF23; Kidney; Mineral metabolism
• ISSN: 0031-6768; 1432-2013
• DOI: 10.1007/s00424-018-2171-7

Fibroblast growth factor 23 (FGF23) is a major endocrine regulator of phosphate and 1,25 (OH)
2
vitamin D
3
metabolism and is mainly produced by osteocytes. Its production is upregulated by a variety of factors including 1,25 (OH)
2
vitamin D
3
, high dietary phosphate intake, and parathyroid hormone (PTH). Recently, iron deficiency and hypoxia have been suggested as additional regulators of FGF23 and a role of erythropoietin (EPO) was shown. However, the regulation of FGF23 by EPO and the impact on phosphate and 1,25(OH)
2
vitamin D
3
are not completely understood. Here, we demonstrate that acute administration of recombinant human EPO (rhEPO) to healthy humans increases the C-terminal fragment of FGF23 (C-terminal FGF23) but not intact FGF23 (iFGF23). In mice, rhEPO stimulates acutely (24 h) C-terminal FGF23 but iFGF23 only after 4 days without effects on PTH and plasma phosphate. 1,25 (OH)
2
D
3
levels and αklotho expression in the kidney decrease after 4 days. rhEPO induced FGF23 mRNA in bone marrow but not in bone, with increased staining of FGF23 in CD71
+
erythroid precursors in bone marrow. Chronic elevation of EPO in transgenic mice increases iFGF23. Finally, acute injections of recombinant FGF23 reduced renal EPO mRNA expression. Our data demonstrate stimulation of FGF23 levels in mice which impacts mostly on 1,25 (OH)
2
vitamin D
3
levels and metabolism. In humans, EPO is mostly associated with the C-terminal fragment of FGF23; in mice, EPO has a time-dependent effect on both FGF23 forms. EPO and FGF23 may form a feedback loop controlling and linking erythropoiesis and mineral metabolism.